Abstract: The disclosed martensitic stainless steel is defined in its composition is by specified ranges of weight percentages of C; Mn; Si; ?Mn+Si; ?S; 10,000×Mn×S; P; Cr, with [Cr?10.3?80*(C+N)2]?(Mn+Ni); Ni; Mo; Mo+2W; Cu; Ti; V; Zr; Al; O; Ta; Nb; (Nb+Ta)/(C+N); Nb; N; Co; Cu+Co; Cu+Co+Ni; B; rare earths+Y; Ca; the remainder being iron and impurities resulting from processing. Its microstructure includes at least 75% martensite, at most 20% ferrite and at most 0.5% carbides, the size of the ferrite grains being between 4 and 80 ?m, preferably between 5 and 40 ?m. Also disclosed is a method of manufacturing such steel.

Abstract: This invention relates a compostable lid for sealing a beverage capsule or a beverage pad wherein the lid comprises a natural-fiber based support obtainable by: (i) providing a first fibrous base sheet comprising natural fiber material sensitive to a gelatinizing agent; (ii) treating the first base sheet with a gelatinizing agent to give a treated first fibrous base sheet comprising gelatinized material; (iii) providing a second fibrous base sheet; (iv) contacting the treated first fibrous base sheet and the second base sheet with each other; (v) causing at least partial migration of the gelatinized material from the treated first fibrous base sheet into the second fibrous base sheet to give a multilayer product; and (vi) neutralizing and/or washing the product thus obtained and then drying it.

Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one polar moiety as a ligand.

Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

Abstract: Conjugates of an active agent attached to a targeting moiety, such as at least one HSP90 binding moiety, via a linker, have been designed. Such conjugates can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

Abstract: A method for manufacturing a martensitic stainless steel part, according to which a stainless steel sheet is prepared with the following composition: 0.005%?C?0.3%; 0.2%?Mn?2.0%; traces?Si?1.0%; traces?S?0.01%; traces?P?0.04%; 10.5%?Cr?17.0%; traces?Ni?4.0%; traces?Mo?2.0%; Mo+2×W?2.0%; traces?Cu?3%; traces?Ti?0.5%; traces?Al?0.2%; traces?O?0.04%; 0.05%?Nb?1.0%; 0.05%?Nb+Ta?1.0%; 0.25%?(Nb+Ta)/(C+N)?8; traces?V?0.3%; traces?Co?0.5%; traces?Cu+Ni+Co?5.0%; traces?Sn?0.05%; traces?B?0.1%; traces?Zr?0.5%; Ti+V+Zr?0.5%; traces?H?5 ppm; traces?N?0.2%; (Mn+Ni)?(Cr?10.3?80×[(C+N)2]); traces?Ca?0.002%; traces?rare earth and/or Y?0.06%; and the rest being iron and impurities.

Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

Abstract: The disclosed martensitic stainless steel is defined in its composition is by specified ranges of weight percentages of C; Mn; Si; ?Mn+Si; ?S; 10,000×Mn×S; P; Cr, with [Cr—10.3?80*(C+N)2]?(Mn+Ni); Ni; Mo; Mo+2W; Cu; Ti; V; Zr; Al; O; Ta; Nb; (Nb+Ta)/(C+N); Nb; N; Co; Cu +Co; Cu+Co+Ni; B; rare earths +Y; Ca; the remainder being iron and impurities resulting from processing. Its microstructure includes at least 75% martensite, at most 20% ferrite and at most 0.5% carbides, the size of the ferrite grains being between 4 and 80 ?m, preferably between 5 and 40 ?m. Also disclosed is a method of manufacturing such steel.

Abstract: Particles, including nanoparticles and microparticles, and pharmaceutical formulations thereof, containing conjugates of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via a linker have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Abstract: Conjugates of an active agent attached to a targeting moiety, such as an HSP90 binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

Abstract: Targeted constructs and pharmaceutical formulations thereof, comprising at least one conjugate of an active agent such as a therapeutic, prophylactic, or diagnostic agent attached to a targeting moiety via an optional internal linker moiety have been designed which can provide improved temporospatial delivery of the active agent and/or improved biodistribution. Methods of making the targeted constructs and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer or infectious diseases.

Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.

Abstract: The present disclosure relates to novel platinum compositions having a heterocycle ligand and nanoparticles and methods using such compositions, e.g. for treating cancer.

Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one polar moiety as a ligand.

Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein.

Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one reacting group for reacting with a functional group on a protein, engineered protein, antibody, antibody fragment, peptide, agonist, antagonist, aptamer or ligand which may be capable of recognizing a selected target cell population, and/or derivatives/analogs/mimics thereof.

Abstract: The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one polar moiety as a ligand.